Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Current Deferred Revenue (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Current Deferred Revenue for 7 consecutive years, with $360000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Current Deferred Revenue rose 928.57% to $360000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $360000.0, a 928.57% increase, with the full-year FY2024 number at $257000.0, down 5.86% from a year prior.
  • Current Deferred Revenue was $360000.0 for Q3 2025 at 4D Molecular Therapeutics, down from $1.1 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $7.1 million in Q1 2021 to a low of $35000.0 in Q3 2024.
  • A 5-year average of $2.1 million and a median of $884000.0 in 2022 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: plummeted 95.95% in 2023, then surged 928.57% in 2025.
  • 4D Molecular Therapeutics' Current Deferred Revenue stood at $5.1 million in 2021, then crashed by 82.63% to $884000.0 in 2022, then tumbled by 69.12% to $273000.0 in 2023, then decreased by 5.86% to $257000.0 in 2024, then surged by 40.08% to $360000.0 in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Current Deferred Revenue are $360000.0 (Q3 2025), $1.1 million (Q2 2025), and $866000.0 (Q1 2025).